Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, vol.352, pp.987-96, 2005. ,
The multi-factorial nature of clinical multidrug resistance in cancer, Drug Resist Updat, vol.46, p.100645, 2019. ,
Guidelines and definitions for research on epithelial-mesenchymal transition, Nat Rev Mol Cell Biol, vol.21, pp.341-52, 2020. ,
Phenotypic Plasticity: driver of cancer initiation, progression, and therapy resistance, Cell Stem Cell, vol.24, pp.65-78, 2019. ,
Intratumor heterogeneity: the rosetta stone of therapy resistance, Cancer Cell, vol.37, pp.471-84, 2020. ,
EMT transition states during tumor progression and metastasis, Trends Cell Biol, vol.29, pp.212-238, 2019. ,
Targeting cancer stemness in the clinic: from hype to hope, Cell Stem Cell, vol.24, pp.25-40, 2019. ,
A view on drug resistance in cancer, Nature, vol.575, pp.299-309, 2019. ,
Cell death-based treatment of glioblastoma, Cell Death Dis, vol.9, p.121, 2018. ,
Decoding and unlocking the BCL-2 dependency of cancer cells, Nat Rev Cancer, vol.13, pp.455-65, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-02481124
Radiation-induced PGE2 sustains human glioma cells growth and survival through EGF signaling, Oncotarget, vol.6, pp.6840-6849, 2015. ,
Tumor cells hijack enteric glia to activate colon cancer stem cells and stimulate tumorigenesis, EBioMedicine, vol.49, pp.172-88, 2019. ,
Definitions and guidelines for research on antibiotic persistence, Nat Rev Microbiol, vol.17, pp.441-449, 2019. ,
URL : https://hal.archives-ouvertes.fr/pasteur-02558489
Repression of stress-induced LINE-1 expression protects cancer cell subpopulations from lethal drug exposure, Cancer Cell, vol.32, pp.221-258, 2017. ,
Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer, Theranostics, vol.10, pp.6261-77, 2020. ,
Dormant, quiescent, tolerant and persister cells: four synonyms for the same target in cancer, Biochem Pharmacol, vol.162, pp.169-76, 2019. ,
URL : https://hal.archives-ouvertes.fr/inserm-01947474
Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance, J Cell Commun Signal, vol.12, pp.133-174, 2018. ,
Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells, Nat Commun, vol.7, p.10690, 2016. ,
Persister cells, Annu Rev Microbiol, vol.64, pp.357-72, 2010. ,
Slow growth causes bacterial persistence, Sci Signal, vol.12, p.1167, 2019. ,
Temozolomide resistance in Glioblastoma Multiforme, Genes Dis, vol.3, pp.198-210, 2016. ,
Temozolomide: a novel oral alkylating agent, Expert Rev Anticancer Ther, vol.1, pp.13-22, 2001. ,
Aberrant base excision repair pathway of oxidatively damaged DNA: implications for degenerative diseases, Free Radic Biol Med, vol.107, pp.266-77, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02393543
Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods, J Neurooncol, vol.97, pp.311-333, 2010. ,
URL : https://hal.archives-ouvertes.fr/inserm-00435222
Folate supplementation limits the tumourigenesis in rodent models of gliomagenesis, Eur J Cancer, vol.48, pp.2431-2472, 2012. ,
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents, N Engl J Med, vol.343, pp.1350-1354, 2000. ,
Folate supplementation limits the aggressiveness of glioma via the remethylation of DNA repeats element and genes governing apoptosis and proliferation, Clin Cancer Res, vol.15, pp.3519-3548, 2009. ,
MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma, Int J Cancer, vol.127, pp.2106-2124, 2010. ,
MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome, Int J Cancer, vol.122, pp.1391-1400, 2008. ,
The p53 pathway in glioblastoma, Cancers (Basel), vol.10, p.297, 2018. ,
Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions, PLoS One, vol.15, p.229534, 2020. ,
p53 small molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts, Cancer Res, vol.68, pp.10034-10043, 2008. ,
Interaction between p53 N terminus and core domain regulates specific and nonspecific DNA binding, Proc Natl Acad Sci, vol.116, pp.8859-68, 2019. ,
MGMT gene silencing and benefit from temozolomide in glioblastoma, N Engl J Med, vol.352, pp.997-1003, 2005. ,
Temporal stability of MGMT promoter methylation in glioblastoma patients undergoing STUPP protocol, J Neurooncol, vol.137, pp.233-273, 2018. ,
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma, Nat Commun, vol.9, p.2949, 2018. ,
A distinct DNA methylation shift in a subset of glioma CpG island methylator phenotypes during tumor recurrence, Cell Rep, vol.23, pp.637-51, 2018. ,
DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma, Mol Cancer, vol.19, p.28, 2020. ,
Diuron exposure and Akt overexpression promote glioma formation through DNA hypomethylation, Clin Epigenetics, vol.11, p.159, 2019. ,
URL : https://hal.archives-ouvertes.fr/inserm-02480992
Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells, Oncotarget, vol.8, pp.34896-910, 2017. ,
Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance, Cell Stem Cell, vol.20, pp.233-279, 2017. ,
MGMT promoter methylation in serum and cerebrospinal fluid as a tumor-specific biomarker of glioma, Biomed Rep, vol.3, pp.543-551, 2015. ,
MiR-370-3p is a therapeutic tool in anti-glioblastoma therapy but is not an intratumoral or cell-free circulating biomarker, Mol Ther Nucleic Acids, vol.13, pp.642-50, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-01982015
The mitochondrial pathways of apoptosis, Adv Exp Med Biol, vol.942, pp.157-83, 2012. ,
TRAIL and FasL functions in cancer and autoimmune diseases: towards an increasing complexity, Cancers (Basel), vol.11, p.639, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02189531
Autophagic and apoptotic pathways as targets for chemotherapy in glioblastoma, Int J Mol Sci, vol.19, p.3773, 2018. ,
Prognostic impact of the expression/phosphorylation of the BH3-only proteins of the BCL-2 family in glioblastoma multiforme, Cell Death Dis, vol.3, p.421, 2012. ,
Expression of bcl-2, bax and bcl-xl in human gliomas: a re-appraisal, J Neurooncol, vol.52, pp.129-168, 2001. ,
The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death, Cancer Res, vol.66, pp.2757-64, 2006. ,
Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma, Oncotarget, vol.5, pp.2428-2463, 2014. ,
Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice, Nat Med, vol.22, pp.78-83, 2016. ,
Finding a Panacea among combination cancer therapies, Cancer Res, vol.72, pp.18-23, 2012. ,
Targeting autophagy for combating chemoresistance and radioresistance in glioblastoma, Apoptosis, vol.23, pp.563-75, 2018. ,
Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis, Cell Death Dis, vol.9, p.841, 2018. ,
An interplay between senescence, apoptosis and autophagy in glioblastoma multiforme -role in pathogenesis and therapeutic perspective, Int J Mol Sci, vol.19, p.889, 2018. ,
Autophagy in glioma cells: an identity crisis with a clinical perspective, Cancer Lett, vol.428, pp.139-185, 2018. ,
Temozolomide induces senescence and repression of DNA repair pathways in glioblastoma cells via activation of ATR-CHK1, p21, and NF-?B, Cancer Res, vol.79, pp.99-113, 2019. ,
Irradiation induces glioblastoma cell senescence and senescence-associated secretory phenotype, Tumour Biol, vol.37, pp.5857-67, 2016. ,
Targeting anticancer drug-induced senescence in glioblastoma therapy, Oncotarget, vol.9, pp.37466-37473, 2018. ,
Suppression of autophagy impedes glioblastoma development and induces senescence, Autophagy, vol.12, pp.1431-1440, 2016. ,
A phase 0 trial of Ribociclib in recurrent glioblastoma patients incorporating a tumor pharmacodynamic-andpharmacokinetic-guided expansion cohort, Clin Cancer Res, vol.25, pp.5777-86, 2019. ,
Mitochondrial energy metabolism and apoptosis regulation in glioblastoma, Brain Res, vol.1595, pp.127-169, 2015. ,
Efficient mitochondrial glutamine targeting prevails over glioblastoma metabolic plasticity, Clin Cancer Res, vol.23, pp.6292-304, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01595798
Human glioblastoma arises from subventricular zone cells with low-level driver mutations, Nature, vol.560, pp.243-250, 2018. ,
Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis, J Neurochem, vol.144, pp.93-104, 2018. ,
Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma, Cell Death Dis, vol.6, p.1601, 2015. ,
Intracellular redox-balance involvement in temozolomide resistancerelated molecular mechanisms in glioblastoma, Cells, vol.8, p.1315, 2019. ,
Metabolic modulation of glioblastoma with dichloroacetate, Sci Transl Med, vol.2, pp.31-34, 2010. ,
Comparison of spheroids formed by rat glioma stem cells and neural stem cells reveals differences in glucose metabolism and promising therapeutic applications, J Biol Chem, vol.287, pp.33664-74, 2012. ,
Control of glioma cell death and differentiation by PKM2-Oct4 interaction, Cell Death Dis, vol.5, p.1036, 2014. ,
RUNX1-Evi-1 fusion gene inhibited differentiation and apoptosis in myelopoiesis: an in vivo study, BMC Cancer, vol.15, p.970, 2015. ,
D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH, Cell Death Dis, vol.6, p.1704, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-01818661
Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells, Neuro Oncol, vol.19, pp.43-54, 2017. ,
Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells, Nat Cell Biol, vol.10, pp.619-643, 2008. ,
Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes, PLoS One, vol.7, p.50999, 2012. ,
Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy, J Natl Cancer Inst, vol.107, p.135, 2015. ,
Exosomes decrease sensitivity of breast cancer cells to adriamycin by delivering microRNAs, Tumour Biol, vol.37, pp.5247-56, 2016. ,
A review of Glioblastoma immunotherapy, J Neurooncol, 2020. ,
NKG2D controls natural reactivity of V?9V?2 T lymphocytes against mesenchymal glioblastoma cells, Clin Cancer Res, vol.25, pp.7218-7246, 2019. ,
Impact of temozolomide on immune response during malignant glioma chemotherapy, Clin Dev Immunol, vol.2012, p.831090, 2012. ,
Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models, Clin Cancer Res, vol.20, pp.1555-65, 2014. ,
Temozolomide for immunomodulation in the treatment of glioblastoma, Neuro Oncol, vol.20, pp.1566-72, 2018. ,
Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells, Cancer Lett, vol.433, pp.176-85, 2018. ,
Impairing temozolomide resistance driven by glioma stem-like cells with adjuvant immunotherapy targeting O-acetyl GD2 ganglioside, Int J Cancer, vol.146, pp.424-462, 2020. ,
URL : https://hal.archives-ouvertes.fr/inserm-02168202
Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition, Neuro Oncol, vol.21, pp.730-771, 2019. ,
Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications, Neuro Oncol, vol.22, pp.180-94, 2020. ,
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, Nature, vol.444, pp.756-60, 2006. ,
Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer, Genes Dev, vol.33, pp.591-609, 2019. ,
The hypoxic peri-arteriolar glioma stem cell niche, an integrated concept of five types of niches in human glioblastoma, Biochim Biophys Acta Rev Cancer, vol.1869, pp.346-54, 2018. ,
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1, Cancer Cell, vol.17, pp.98-110, 2010. ,
Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma, Cell Death Dis, vol.11, p.19, 2020. ,
Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma, EMBO J, vol.37, p.98772, 2018. ,
The multifaceted metabolism of glioblastoma, Adv Exp Med Biol, vol.1063, pp.59-72, 2018. ,
New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer, Nat Rev Mol Cell Biol, vol.20, pp.69-84, 2019. ,
Proneural-mesenchymal transition: phenotypic plasticity to acquire multitherapy resistance in glioblastoma, Int J Mol Sci, vol.20, p.2746, 2019. ,
Multidimensional communication in the microenvirons of glioblastoma, Nat Rev Neurol, vol.14, pp.482-95, 2018. ,